Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603).

Michele Reni,Stefano Cereda,Michele Milella,Anna Novarino,Alessandro Passardi,Andrea Mambrini,Giuseppe Di Lucca,Laura Ferrari,Carmen Belli,Marco Danova,Francesca Bergamo,Enrico Franceschi,Bianca Rovati,Clara Fugazza,Domenica Ceraulo,Eugenio Villa

Journal of Clinical Oncology（2017）

引用 7|浏览51

暂无评分

摘要

4017 Background: Combination chemotherapy (CT) prolonged progression-free survival at 6 months (PFS6) of patients (pts) with MPA from 50%. To prolong CT over 6 month...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要